CN106072654A - 6 ' sialylated lactose purposes in infants and young's nutrient - Google Patents
6 ' sialylated lactose purposes in infants and young's nutrient Download PDFInfo
- Publication number
- CN106072654A CN106072654A CN201610421321.8A CN201610421321A CN106072654A CN 106072654 A CN106072654 A CN 106072654A CN 201610421321 A CN201610421321 A CN 201610421321A CN 106072654 A CN106072654 A CN 106072654A
- Authority
- CN
- China
- Prior art keywords
- purposes
- alimentation composition
- oligosaccharide
- aforementioned
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 title claims abstract description 28
- 239000008101 lactose Substances 0.000 title claims abstract description 28
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 72
- 235000016709 nutrition Nutrition 0.000 claims abstract description 10
- 230000035764 nutrition Effects 0.000 claims abstract description 10
- 229920001542 oligosaccharide Polymers 0.000 claims description 52
- 150000002482 oligosaccharides Chemical class 0.000 claims description 50
- 239000002253 acid Substances 0.000 claims description 25
- 229930182830 galactose Natural products 0.000 claims description 25
- 150000001720 carbohydrates Chemical class 0.000 claims description 21
- 235000014633 carbohydrates Nutrition 0.000 claims description 21
- 235000013350 formula milk Nutrition 0.000 claims description 16
- 235000018102 proteins Nutrition 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 150000002632 lipids Chemical class 0.000 claims description 13
- 229920001277 pectin Polymers 0.000 claims description 7
- 239000001814 pectin Substances 0.000 claims description 7
- 235000010987 pectin Nutrition 0.000 claims description 7
- 239000007857 degradation product Substances 0.000 claims description 5
- -1 galacturonic acid Oligosaccharide Chemical class 0.000 claims description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000020256 human milk Nutrition 0.000 description 26
- 210000004251 human milk Anatomy 0.000 description 26
- 230000002378 acidificating effect Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 10
- 229940077731 carbohydrate nutrients Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 235000013336 milk Nutrition 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- SFMRPVLZMVJKGZ-JRZQLMJNSA-N Sialyllacto-N-tetraose b Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]2O)O)O1 SFMRPVLZMVJKGZ-JRZQLMJNSA-N 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 8
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 7
- QUOQJNYANJQSDA-MHQSSNGYSA-N Sialyllacto-N-tetraose a Chemical compound O1C([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](OC2[C@H]([C@H](OC3[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@@H]1O QUOQJNYANJQSDA-MHQSSNGYSA-N 0.000 description 7
- 229920001202 Inulin Polymers 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 6
- 229940029339 inulin Drugs 0.000 description 6
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 235000004252 protein component Nutrition 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- LKOHREGGXUJGKC-UHFFFAOYSA-N Lactodifucotetraose Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)OC2CO)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O LKOHREGGXUJGKC-UHFFFAOYSA-N 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 102000003838 Sialyltransferases Human genes 0.000 description 3
- 108090000141 Sialyltransferases Proteins 0.000 description 3
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 3
- LKOHREGGXUJGKC-NTQZDHPLSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)C(O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O LKOHREGGXUJGKC-NTQZDHPLSA-N 0.000 description 3
- RQNFGIWYOACERD-OCQMRBNYSA-N alpha-L-Fucp-(1->4)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)[C@@H]2NC(C)=O)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O RQNFGIWYOACERD-OCQMRBNYSA-N 0.000 description 3
- IEQCXFNWPAHHQR-YKLSGRGUSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O IEQCXFNWPAHHQR-YKLSGRGUSA-N 0.000 description 3
- DMYPRRDPOMGEAK-XWDFSUOISA-N beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@H](O[C@H]4[C@H]([C@H](O)[C@H](O)[C@H](C)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)OC(O)[C@@H]1O DMYPRRDPOMGEAK-XWDFSUOISA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229960002737 fructose Drugs 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- OQIUPKPUOLIHHS-UHFFFAOYSA-N lacto-N-difucohexaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(CO)OC(OC3C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C3O)O)C2NC(C)=O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O OQIUPKPUOLIHHS-UHFFFAOYSA-N 0.000 description 3
- DMYPRRDPOMGEAK-UHFFFAOYSA-N lacto-N-difucohexaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(C(O)C(O)C(CO)O4)O)C(OC4C(C(O)C(O)C(C)O4)O)C(CO)O3)NC(C)=O)C(O)C(CO)O2)O)C(CO)OC(O)C1O DMYPRRDPOMGEAK-UHFFFAOYSA-N 0.000 description 3
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 2
- FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- AXQLFFDZXPOFPO-FSGZUBPKSA-N beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO AXQLFFDZXPOFPO-FSGZUBPKSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 108010057005 beta-galactoside alpha-2,3-sialyltransferase Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 2
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- WMYQZGAEYLPOSX-JOEMMLBASA-N lex-lactose Chemical compound OC1[C@@H](O)[C@@H](O)[C@@H](C)O[C@@H]1O[C@H]1C(O[C@H]2[C@@H](C(O)C(O)C(CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](OC(C(O)CO)[C@H](O)[C@@H](O)C=O)OC(CO)C2O)O)C1NC(C)=O WMYQZGAEYLPOSX-JOEMMLBASA-N 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 229940060155 neuac Drugs 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000009589 serological test Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical group OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 241000607568 Photobacterium Species 0.000 description 1
- 241000607606 Photobacterium sp. Species 0.000 description 1
- 229920000377 Sinistrin Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100027107 Type 2 lactosamine alpha-2,3-sialyltransferase Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000001847 bifidogenic effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- FCIROHDMPFOSFG-LAVSNGQLSA-N disialyllacto-N-tetraose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@H]3[C@@H]([C@@H](O)C(O)O[C@@H]3CO)O)O[C@H](CO)[C@@H]2O)O)O1 FCIROHDMPFOSFG-LAVSNGQLSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001448 refractive index detection Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pediatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of 6 ' sialylated lactose purposes in infants and young's nutrient.The invention provides the alimentation composition that nutrition is provided for infants and young, wherein apply suitable 6 ' SL absolute magnitudes and the 6 ' SL relative quantity than 3 ' SL.
Description
The application is the of entitled " 6 '-sialylated lactose purposes in infants and young's nutrient "
The divisional application of No. 2011800210644 applications for a patent for invention.Original application correspondence international application PCT/NL2011/050285, Shen
Please be on April 27th, 2011 day, priority date be on April 27th, 2010.
Technical field
The invention belongs to the field of infants and young's nutrient.
Background technology
Sialylated oligosaccharide is present in the Ruzhong of mammal and has been found to have biologic importance.Known it
There is prebiotic activity, and be described bifidobacterium growth effect (bifidogenic effect).Known sialylated
Oligosaccharide also has antisticking effect, thus plays in the intestinal infection that suppression or prevention are caused by pathogen and/or toxin
Important function.Known sialylated oligosaccharide concentration in such as Lac Bovis seu Bubali is the lowest, but concentration is the highest in human milk.Due to
Most infants formula is prepared with milk elements, so compared with breast-fed babies, the baby of formula feeding has
Relatively low sialylated oligosaccharide intake.The important member of sialylated oligosaccharide be 3 '-sialylated lactose (3 '-SL) and
6 '-sialylated lactose (6 '-SL).
Mart í n-Sosa et al (2003) J Dairy Sci 86:52-59 has carried out one about different in age of sucking
The comparative study of the sialylated oligosaccharide content of Lac Bovis seu Bubali and human milk in stage.
Asakuma et al. (2007) Biosci Biotechnol Biochem, 71 (6): 1447-1451 have studied
The change of people's just sialylated concentration of oligosaccharide in Ruzhong in first three day of age of sucking.Find that the concentration of 3 '-sialylated lactose exists
Within 1st day, apparently higher than the 2nd day and the 3rd day, and the mean concentration of 3 '-SL was about 297mg/L in puerperal first three sky.6 '-saliva
The level of liquid acidifying lactose is at the 3rd day higher than the 1st day, and in puerperal first three sky, the mean concentration of 6 '-SL is 370mg/L.
WO 2009/059996 relates to the alimentation composition of the secondary infection after prophylaxis of viral infections, including sialic acid
Change oligosaccharide, particularly 3 '-SL and 6 '-SL.
In view of the purpose in order to prepare the infants and young's food being similar to human milk as far as possible, this area is it has been recognized that make
This group food is rich in containing sialic oligosaccharide, the most sialylated lactose.In view of this point, such as at WO 2009/
Describe in 113861 and separate the most sialylated lactose from Ruzhong to make human infant nutrition rich in sialylated lactose
Method.And do not differentiate between 3 '-SL and 6 '-SL.
Summary of the invention
Surprisingly, it was found that in order to 6 ' actually existed in human milk-sialylated lactose (6 '-SL) quantity
Consistent, need 6 '-SL of the higher amount that preparation ratio is used now in infant formula.
Further, the present inventors have additionally discovered that, be applied to now infant formula 3 '-SL and 6 '-SL relative quantity or
Ratio is compared, and actually exists in the relative quantity of 3 ' in human milk-sialylated lactose (3 '-SL) and 6 '-SL and becomes 3 '-SL and account for phase
To relatively low ratio.
Therefore, in short, the inventors discovered that, in order to be similar to human milk as far as possible and in order to preferably reach sialic acid
Change the more optimal prebiotic activity of oligosaccharide (preferably 6 '-SL and 3 '-SL), bifidobacterium growth effect and/or anti-stick
Effect, infant formula needs to prepare, especially with regard to sialylated oligosaccharide (preferably being different from present practice
6 '-SL and 3 '-SL) amount.In doing so, will realize improve intestinal physiology and/or health, preferably implement suppression or
Improvement in terms of the intestinal infection that prevention is caused by pathogen and/or toxin.
Detailed description of the invention
Therefore, the present invention relates to a kind of method providing nutrition for baby, described method includes that giving one comprises at least
The compositions of 1g/L 6 '-sialylated lactose (6 '-SL), wherein the weight ratio of 6 '-SL:3 '-SL is higher than 2.
The present invention can also be expressed as, and relates to the compositions that one comprises 6 '-sialylated lactose (6 '-SL) and is used for preparing
There is provided the purposes in the alimentation composition of nutrition, described alimentation composition to comprise at least 1g/L 6 '-SL for baby, wherein 6 '-
The weight ratio of SL:3 '-SL is higher than 2.
The present invention can also be expressed as, and a kind of comprises at least 1g/L6 '-sialylated breast for provide nutrition for baby
The compositions of sugar (6 '-SL), wherein the weight ratio of 6 '-SL:3 '-SL is higher than 2.
The invention still further relates to a kind of alimentation composition, be preferably a kind of infant formula, it is the most caloric that it comprises offer
The lipid of 35%-50%, it is provided that the protein of total caloric 7.5%-12.5%, and total caloric 40%-is provided
The digestible carbohydrates of 55%, comprises at least 1g/L 6 '-SL further, and wherein the ratio of 6 '-SL:3 '-SL is higher than 2.
6’-SL
Described alimentation composition of the present invention preferably comprises at least 1g/L 6 '-SL, more preferably at least 1.1g/L.This
Concentration, more like human milk, is commonly used in infant milk formula, and is therefore preferred.Described alimentation composition of the present invention is preferably
Comprise less than 3g/L 6 '-SL, more preferably less than 2.5g/L, more preferably less than 2g/L, more preferably less than 1.5g/L 6 '-
SL, more preferably between 1.1g/L to 1.5g/L, more preferably between 1.1g/L to 1.4g/L, more preferably at 1.2g/L
Between 1.4g/L.
Described alimentation composition of the present invention further preferably includes 3 '-SL, and the weight ratio of 6 '-SL:3 '-SL is higher than
2.Preferably, the weight ratio of 6 '-SL:3 '-SL is higher than 2.5, preferably higher than 2.8, preferably higher than 3, preferably higher than 3.5,
It is preferably higher than 4.Preferably, the weight ratio of 6 '-SL:3 '-SL is less than 6.It is preferably lower than 5.5, is preferably lower than 5.Preferably,
The weight ratio of 6 '-SL:3 '-SL is between 2.5 to 5.5, preferably between 3 to 5.
In one embodiment, the described present composition comprises based on described compositions overall dry weight at least
The 6 '-SL of 0.7wt%, are based preferably on described compositions overall dry weight between 0.7wt% to 2.1wt%, preferably exist
Between 0.8wt% to 1.5wt%, preferably between 0.85wt% to 1.0wt%.
Described alimentation composition of the present invention can be prepared by the method preparing infant milk formula, and described method includes a) adding
Add the non-digestible property oligosaccharide from Lac Bovis seu Bubali, b) add 6 '-SL.
6 '-SL are commercially available and can buy from Sigma-Aldrich.6 '-SL can also be by through metabolism
The escherichia coli (E.coli) of transformation synthesize, described escherichia coli expression Photobacterium (Photobacterium sp.)
The multi-functional sialyltransferase of one of JT-ISH-224, as Drouillard et al. submits at present in version
Described in Carbohydrate Research.The evidence of correction is available from http://www.sciencedirect.com/
science？_ ob=ArticleURL&_udi=B6TFF-4YG1M15-1&_user=3112367&_coverD ate=02%
2F24%2F2010&_rdoc=1&_fmt=high&_orig=search&_sort=d&_doca nchor=&view=
C&_searchS trId=1311365313&_rerunOrigin=scholar.google&_acct=C00005 9787&_
Version=1&_urlVersion=0&_userid=3112367&md5=
ec8dccad77c1e06a5b102da46d8403b6。
Non-digestible property oligosaccharide in addition to 6 '-sialylated lactose and 3 '-sialylated lactose
Described alimentation composition preferably includes non-digestible property oligosaccharide (NDO, non-in addition to 6 '-SL and 3 '-SL
digestible oligosaccharides).Preferably, described NDO stimulation of bifidobacteria in addition to 6 '-SL and 3 '-SL
And/or the growth of the growth of lactobacillus, more preferably stimulation of bifidobacteria.Bacillus bifidus and/or the increasing of lactobacillus content
Add the formation stimulating healthy gut flora.Described NDO is preferably the most digested in intestinal or the most digested, described
Digestion is to carry out, described NDO by being present in the acid of people's upper digestive tract (particularly in small intestinal stomach function regulating) or the effect of digestive enzyme
Fermented by people's intestinal microbial population.Such as, sucrose, lactose, maltose and common maltodextrin are considered as digestible.
Preferably, the described present composition comprises DP in the range of 2 to 250, the non-digestible property of more preferably 2 to 60
Oligosaccharide.Described non-digestible property oligosaccharide is preferably selected from least one of following component, more preferably at least two kinds, preferably
It is at least three kinds: oligofructose, oligomeric galactose, oligomeric xylose, arabinooligosaccharides, arabinooligosaccharides galactose, oligomeric
Glucose, low Chitosan, oligomeric glucose mannose, oligomeric galactose mannose, Oligomeric manna sugar, containing sialic oligosaccharide
And uronic acid oligosaccharides.The group of oligofructose includes inulin, and the group of oligomeric galactose includes transgalactooligosac,harides or β-low
Poly-galactose, the group of oligomeric glucose includes cyclodextrin, gentian oligose and aspergillus niger oligosaccharide and non-digestible Xing Ju Portugal
Grape sugar, the group of oligomeric galactose mannose includes the guar gum of partial hydrolysis, and the group of uronic acid oligosaccharides includes galacturonic acid
Oligosaccharide and pectin degradation product.
It is highly preferred that the described present composition includes selected from oligofructose, β-oligomeric galactose and uronic acid oligosaccharides
In at least one, more preferably at least two kinds, most preferably three kinds.It is highly preferred that described compositions includes β-oligomeric gala
Sugar.
In a preferred embodiment, described compositions includes the mixture of inulin and short chain oligofructose.One
In individual preferred embodiment, described compositions includes the mixture of oligomeric galactose and oligofructose, wherein said oligomeric fruit
Sugar is selected from short chain oligofructose and inulin, preferably inulin.The mixture of the non-digestible property oligosaccharide that at least two is different has
Have stimulated the degree that the beneficial bacteria in intestinal microbial population reaches bigger sharply.Preferably, different non-digestible of the two
In the mixture of property oligosaccharide (preferably oligomeric galactose and oligofructose), both weight ratios are between 25 to 0.05, more
Preferably between 20 to 1.Oligomeric galactose (preferably β-oligomeric galactose) more can stimulation of bifidobacteria.Preferably, institute
State oligomeric galactose (preferably β-oligomeric galactose) that the present composition includes that the degree of polymerization (DP) is 2 to 10 and/or DP is 2
To the oligofructose of 60.
Described oligomeric galactose is preferably β-oligomeric galactose.In an especially preferred embodiment, send out for described
Bright compositions includes β-oligomeric galactose ([galactose] n-glucose；Wherein n is the integer from 2 to 60, i.e. 2,3,4,5,
6、....、59、60；Preferably n is selected from 2,3,4,5,6,7,8,9 and 10), wherein said galactose units is mainly by β key
(linkage) link together.β-oligomeric galactose is also referred to as transgalactooligosac,harides (TOS).Such as, β-oligomeric galactose
It is with trade mark Vivinal(TM)(Borculo Domo Ingredients, Netherlands) sells.Another suitable source is
Bi2Munno(Classado).Preferably, described TOS includes β-Isosorbide-5-Nitrae based on total key number meter at least 80% and β-1,6 keys, more
It is preferably at least 90%.
In order to comprise, to have DP or average DP be 2 to 250 to oligofructose, preferably 2 to 100, even more preferably 10 to 60
The NDO of fructose units chain of β-connection.Oligofructose includes the polyfructosan of inulin, levan and/or mixed type.A kind of special
Not preferably oligofructose is inulin.The oligofructose being suitable for described compositions is also commercially available, such asHP(Orafti).Preferably, the average poly-DP of described oligofructose is more than 20.
Uronic acid oligosaccharides preferably obtains from pectin degradation product.The most described present composition preferably includes DP
It it is the pectin degradation product of 2 to 100.Preferably, described pectin degradation product is from apple pectin, beet pectin and/or citrus fruit
Prepared by glue.Preferably, described uronic acid oligosaccharides is galactoronic acid oligosaccharides.Preferably, described compositions include FL with
And the one in oligomeric galactose and uronic acid oligosaccharides.
Except 6 '-SL and 3 '-SL, most preferably, described compositions includes β-oligomeric galactose, oligofructose and alduronic acid
Oligosaccharide.Find described conjugate and 6 '-SL and 3 '-SL synergism.β-oligomeric galactose: oligofructose: uronic acid oligosaccharide
The weight ratio of sugar is preferably (20 to 2): 1:(1 to 20), more preferably (20 to 2): 1:(1 to 10), even more preferably (20 arrive
2): 1:(1 to 3), it is even more preferably (12 to 7): 1:(1 to 2).Most preferably, described weight ratio is about 9:1:1.1.
Preferably, the non-digestible property oligosaccharide that the every 100ml of described alimentation composition comprises 100mg to 4g (includes 6 '-SL
With 3 '-SL), the non-digestible property that more preferably 500mg to 3g, the most every 100ml comprise 800mg to 2g is oligomeric
Sugar.Based on dry weight meter, described compositions preferably comprises the non-digestible property oligosaccharide of 0.5wt% to 25wt% and (includes 6 '-SL
With 3 '-SL), more preferably 1wt% to 15wt%, even more preferably 5wt% to 10wt%.The non-digestible property of relatively low amount is low
In terms of polysaccharide beneficial bacteria in stimulating flora (microbiota) less effective, but too high amount will cause flatulence with
The side effect of abdominal discomfort.
Alimentation composition
Described alimentation composition is not human milk.Described alimentation composition of the present invention preferably gives through enteral, the most oral
Give.
Described alimentation composition of the present invention is preferably infant formula.Described alimentation composition of the present invention can be advantageously used for
The complete nutrition thing of baby.The described present composition preferably comprises lipid components, protein component becomes with carbohydrate
Divide, and the present composition gives the most in liquid form.The present invention includes being dried food, preferably powder, and it is with closing
In the explanation that described dry foodstuff mixture is mixed with the liquid (preferably water) being suitable for.
Described alimentation composition of the present invention preferably comprises lipid, protein and digestible carbohydrates, wherein said
Lipid components provide the most caloric 5% to 50%, described protein component provide the most caloric 5% to 50%, described in disappear
The property changed carbohydrate component provides the most caloric 15% to 85%.Advantageously, described lipid components provides the most caloric
20% to 50%, described protein component provides the most caloric 5% to 30%, and described digestible carbohydrates composition provides
The most caloric 30% to 70%.Preferably, described lipid components provides the most caloric 35% to 50%, and described protein becomes
Dividing and provide the most caloric 7.5% to 12.5%, described digestible carbohydrates composition provides the most caloric 40% to arrive
55%.Account for total caloric % for calculating described protein component, need to consider to be provided by described protein, peptide and aminoacid
Gross energy.
Described alimentation composition preferably comprises at least one selected from animal lipid (except people's lipid) and vegetable lipid
Lipid.Preferably, the described present composition includes that vegetable lipid is oily with selected from fish oil, animal oil, algae oil, fungal oil and antibacterial
The conjugate of at least one oil.The described present composition preferably includes long-chain polyunsaturated fatty acid (LC-PUFA).
LC-PUFA be a length of 20-24 carbon atom, be preferably 20 or 22 carbon atoms containing two or more unsaturated bonds
Fatty acid or fatty acyl chain.It is highly preferred that the described present composition comprises eicosapentaenoic acid (EPA, n-3), 22 carbon
Acid (DHA, n-3) and/or arachidonic acid (ARA, n-6).
Preferably, the described present composition includes at least 0.1wt% based on total lipid content meter, preferably at least
The LC-with 20-22 carbon atom of 0.25wt%, more preferably at least 0.6wt%, even more desirably at least 0.75wt%
PUFA。
Since it is desired that human milk simulating as much as possible, LC-PUFA's (particularly there is the LC-PUFA of 20-22 carbon atom)
The 3wt% of the 6wt% of content, preferably more than total lipid content, no more than total lipid content.Described LC-PUFA
Can provide as free fatty, as a triglyceride, with triglyceride form, with monoglyceride form, with phospholipid shape
Formula, or provide as one of the above or multiple mixture.The described present composition preferably comprises based on total buttermeter
5wt%-75wt%, the polyunsaturated fatty acid of preferably 10wt%-50wt%.
Protein in described alimentation composition is preferably chosen from: inhuman animal protein (preferably lactoprotein),
Phytoprotein (preferably soybean protein, pea protein and/or rice protein), its hydrolyzate, its free amine group
Acid and mixture thereof.Described alimentation composition preferably contains casein, milk surum, the casein of hydrolysis and/or the milk surum of hydrolysis
Albumen.Preferably, described protein includes whole protein, the most complete milk albumin and/or complete cattle cheese
Protein matter.
Described alimentation composition preferably contain selected from sucrose, lactose, glucose, fructose, corn-syrup solids, starch and
The digestible carbohydrates of maltodextrin, more preferably lactose.
Preferably, described liquid food does not have an excessive caloric density, but still provide enough calorie with
Feeding infant.Therefore, described liquid food preferably has the caloric density between 0.1 to 2.5kcal/ml, the most excellent
Elect the caloric density between 0.5 to 1.5kcal/ml, the caloric density between most preferably 0.6 to 0.8kcal/ml as.
Preferably, described alimentation composition includes nucleotide and/or nucleoside, more preferably nucleotide.Preferably, described group
Compound comprises 5'-CMP, 5 '-UMP, AMP, 5'-GMP and/or 5 '-monophosphate
Inosine, more preferably 5'-CMP, 5 '-UMP, AMP, 5'-GMP and 5 '-mono-phosphorus
Acid inosine.The every 100 grams of described compositions dry weights of the most described compositions comprise 5 to 100mg, more preferably 5 and arrive 50mg, optimum
Selection of land 10 arrives nucleotide and/or the nucleoside of 50mg.
Infants and young
Described the inventive method can be advantageously applied for the child of the human infant of 0-36 month, and more preferably 0-18 is individual
The human infant of the moon, the human infant of more preferably 0-12 month, the human infant of even more preferably 0-6 month.0-36
The baby of the moon includes child.In one embodiment, child's age is more than 6 months by 36 months, or more than within 12 months, arriving
36 months, or more than 18 months to 36 months.In order to pathogen causes the risk of infection be down to minimum, with according to the present invention's
The proportions infant formula of the amount of 6 '-SL and 6 '-SL and 3 '-SL is favourable.Preferably, with the 6 '-SL according to the present invention
Amount and proportions 1 stage of 6 '-SL and 3 '-SL and the infant formula in 2 stages.Preferably, with the 6 '-SL according to the present invention
Amount and the infant formula in proportions 1 stage of 6 '-SL and 3 '-SL.1 stage formulation is for being preferably less than 6 months
Baby provides nutrition, it is therefore preferable to the baby of preferably smaller than 4 months provides nutrition.
Embodiment
Embodiment 1 measures 6 '-SL in breast milk
Material and method
Serological test
In three days puerperal, the women passing through hemagglmination collector test determination Lewis blood group the same day of blood sampling.Make
With corresponding red blood cell suspension (3%-5% red blood cell suspension is in 0.9%NaCl) and monoclonal anti LeaWith anti-LebAntibody
(Immucor,Germany and BAG, Lich, Germany) check hemoagglutination.In room temperature
Hatch 15 minutes.Due to the difference between serological test and chromatogram, it was repeated some blood hemocytees 18-25 month puerperal
Agglutination test (Thurl et al.1998Milchwissenschaft 53:127-129).The women of reception test does not has at that time
Conceived.
Collect sample
All mothers have signed written comment and have agreed to participate in this research, Dresden, Germany university hospital
(university hospital of Dresden, Germany) Ethics Committee have approved this research design.30 Caucasia
Women lives in area, Dresden, and they at 20 to 35 years old and have given birth to healthy babies at the age, and described baby is during studying
For Pure breast feeding.175 whole breast milk samples are mainly acquired in the following time interval including 7 main dates:
3rd day, 2-5 days puerperal；8th day, d6-d9；15th day, d13-d18；22nd day, d20-d26；30th day, d28-d33；60th
My god, d57-d65；90th day, d88-d96.If motherhood have collected the milk sample corresponding to above-mentioned time interval of unnecessary
This, then all of sample is analyzed with the arithmetic mean of instantaneous value of concentration of oligosaccharide.Once to from Frankfurt, Germany
(Frankfurt/Main) area 6 Caucasians, women preliminary examination in, the 7th day puerperal and the 60th day two 24 hours
In cycle, inventor does not find that any obvious oligosaccharide changes (data are unlisted).But, even the least in order to get rid of
Daylight effect, the sampling time in this research is fixed on when feeding the morning.Described milk sample this generally the morning 6-10 point upper
Using (mid-feed) Sampling techniques in feeding to collect between the period of the day from 11 a.m. to 1 p.m, this technology was proved to be a kind of in the past and divided for carbohydrate
The suitable Sampling techniques of analysis.It is extruded into manual for the small sample of about 5-10ml in plastic containers in the centre fed.By milk sample
This is freezing immediately and is stored at 20 DEG C until analyzing.
The chromatography of oligosaccharide
Sample preparation includes gel permeation chromatography purification, and by method (the Thurl et having been described above
Al.1996Anal Biochem.235:202-206) carry out HPAEC analysis.In simple terms, human milk sample is heated at 70 DEG C
30 minutes.In 1ml human milk, add 0.1ml contain internal standard substance stachyose and galacturonic acid aqueous acid.Then by described sample
This centrifugal and ultrafiltration (Millipore Centrifree, 30kDa retain).Use Toyopearl HW 40 (S) post (1,
6x80cm TosoHaas, Stuttgart, Germany) pass through gel permeation chromatography by described protein and lipopenic sample
This fractionated is lactose, neutral oligosaccharide and acidic oligomer sugar.Carbohydrate fraction is washed with water (flow velocity 1ml/min)
And be monitored by refractive index detection.Lactose fraction is abandoned；Neutral and acidic fraction HPAEC-PED analyzes.Acid low
The elution requirement of polysaccharide is 0-8min, 100mM NaOH/20mM NaOAc；8-30min,100mM NaOH/20-80mM
NaOAc；30-55min,100mM NaOH/80-200mM NaOAc；55-60min,100mM NaOH/200mM NaOAc.
In order to monitor the possible artificial hydrolytic degradation to especially sensitive sialylated oligosaccharide, free N-acetyl is neural
Propylhomoserin (Neu5Ac) is quantitative together with acidic oligomer sugar.The Neu5Ac concentration relative constancy (suckling at Lewis blood group Le (a-b+)
In mother, mean concentration is 0.019g/L).The amount of free NeuAc with it be reported that on the same order of magnitude, and in suckling
The NeuAc that the oligosaccharide of about 2% and 4% combines is corresponded respectively to during beginning and after three months.Therefore, it can get rid of by saliva
The obvious degradation to acidic oligomer sugar that acid enzyme effect or heat treated cause.
Statistical analysis
The data analyzed by statistical method are made up of single concentration of oligosaccharide or total by different carbohydrates
The concentration composition of sum.Except total neutral oligosaccharide and total acidic oligomer sugar, the carbon water of the most total nuclear structure and fructose
Compound is added up to respectively: core Lac=Lac+3-FL+2 '-FL+LDFT+3 '-SL+6 '-SL；Core LNT=LNT+LNFP I+
LNFP II+LNDFH I+LNDFH II+LSTa+LSTb+DSLNT；Core LNnT=LNnT+LNFP III+LSTc；Core LNH=
LNH+2’-F-LNH+3’-F-LNH+2’,3’-DF-LNH；Fuc α 1-2Gal=2 '-FL+LDFT+LNFP I+LNDFH I+2 '-
F-LNH+2’,3’-DF-LNH；Fuc α 1-4GlcNAc=LNFP II+LNDFH I+LNDFH II；Fuc α 1-3Glc=3-FL+
LDFT+LNDFH II；Fuc α 1-3GlcNAc=LNFP III+3 '-F-LNH+2 ', 3 '-DF-LNH.
Data set presses two factor tissues, respectively three breast milk groups and seven times of nursing.Further, since different samples
Quantity, data set is the most uneven.(have the ursing mother of Lewis blood group Le (a-b+)) in breast milk group 1 109 samples altogether
In the time being assigned to 10 to 21 sampling ranges, but (there is the non-ursing mother of Lewis blood group Le (a+b-) in the 2nd group；
28 samples) time of nursing by 3-5 sample representation, in the 3rd group, (have the ursing mother of Lewis blood group Le (a-b-)；17
Sample) by 2-3 sample representation.Therefore, the several method of analysis concentration of oligosaccharide meansigma methods is applied.In the 1st group of situation,
Then use Student-Newman-Keuls inspection to compare time of nursing first by one factor analysis of variance (ANOVA)
Meansigma methods.Two factors ANOVA using type III quadratic sum are used for comparing the meansigma methods of three breast milk groups, then calculate minimum
Mean value of square.Therefore, each cell mean without departing from and can compare together completely.Difference Tukey-Kramer of meansigma methods
Method is checked on the significance level of 5%.In whole two variate models, often group and the sample participating in women of each time
Between this concentration, difference produces experimental error.Generally, from oligomeric in the breast milk of the same breast milk group women of given time of nursing
Sugar concentration is alterable height.Due to the interindividual variation that these are huge, although there being notable difference on surface, in same situation
(P > 5%) it is not significantly different between average.
The concentration of oligosaccharide trend during suckling is simulated with regression analysis.Notable regression coefficient has carried out simple line
Property return and matching that secondary and cubic polynomial return and inspection.If regression coefficient is notable (P < 5%), accept this mould
Type.All regression analyses are carried out with single numerical value.All calculating uses SAS system to complete (SAS Institute
Inc.2002-2003SAS/STAT release 9.1SAS Institute Inc.,Cary,NC,USA)。
Result
Carbohydrate fraction
The acidic oligomer sugar of six kinds of as shown in table 1 main non-fucosylations, 3 '-SL, 6 '-SL, LSTa, LSTb,
LSTc, DSLNT, can measure with chromatograph.These carbohydrate summations approximation represents the acidic oligomer sugar in human milk
Fraction.Due to the importance of Lewis blood group system, these sugar are also checked respectively according to described three breast milk groups.All three
The milk sample planting breast type originally demonstrates six kinds of acidic oligomer sugar as above.The amount of described acidic oligomer sugar fraction is three mothers
Breast group do not has significant difference.It addition, all breast milk groups show about three times of similar acid sugar concentration during studying
Decline.
The structure of the acid breast oligosaccharide measured in this research of table 1.
3 '-SL, 3 '-sialylated lactose；6 '-SL, 6 '-sialylated lactose；LSTa-c, sialylated lactose-N-four
Sugar a-c (Sialyllacto-N-tetraoses a-c)；DSLNT, two sialylated lacto-N-tetraose (Disialyllacto-
N-tetraose)。
Acidic saliva acidifying oligosaccharide
The mean concentration of the described six kinds of acidic oligomer sugar measured in this research shows in table 2.Quantitatively 6 '-SL are
The most important acidic carbohydrate in current all Ruzhongs.Detect 3 '-SL of moderate quatity, LSTc and DSLNT, but
The concentration level of LSTa and LSTb is less than 0.1g/L.The individually mean concentration of acid sugar, although in some cases in statistics
Differ on, change the most to a great extent in three breast milk groups, thus confirm about whole carbohydrate level
The result divided.
Similarly, the time effect of breast milk group 1 in table 2 and the trend phase of other breast milk groups (data are unlisted) are shown
Seemingly.The concentration of 6 '-SL reaches peak value in the transition period breast milk of the 8th day, until after Fen Mian the 90th day have dropped at least 3 times.
LSTc, also contains Neu5Ac α 2-6Gal-key, have dropped about 5 times during studying in a similar fashion.3 '-SL are in age of sucking
After 1st stage was decreased obviously, with the horizontal expression of relative constancy in ripe breast milk.LSTa, has Neu5Ac α 2-3Gal-key
Secondary acid sugar, its concentration declines producing one week after, to such an extent as to is not detected by several breast milk samples after one month.
By contrast, the concentration of the LSTb with Neu5Ac α 2-6GlcNAc-key increases in first month and keeps later relatively
Constant.DSLNT, the unique two sialylated carbohydrates analyzed, a kind of mixing between LSTa and LSTb
Structure, demonstrates the highest time graph.
Table 2. acidic oligomer sugar1)Concentration (g/L)
1)The average having same letter is the most significantly different；Student-Newman-Keuls inspection is compared in group 1,
Tukey-Kramer inspection is for the comparison of the least square average (as the result of unbalanced data) of 1-3 group.
Discuss
Acidic oligomer sugar
Six kinds of acidic oligomer sugar that this research measures do not demonstrate great difference in three breast milk groups.This is the most unexpectedly
It is outer because these sugar lack fucose moiety.Acid sugar main in this research, the concentration of 6 '-SL is beyond being reported from other groups
Amount at least twice, but the concentration of DSLNT relatively low (Coppa et al., 1999Acta
Paediatr.Suppl.430:89-94；Martin-Sosa et al.,2003J Dairy Sci.86:52-59；Asakuma
et al.,2007Biosci Biotechnol Biochem.71:1447-1451；Bao et al.,2007Anal
Biochem.370:206-214).The amount that 3 '-SL, amount and Asakuma et al. of LST a, LSTb and LSTc are detected is in approximation
In the range of, the concentration reported less than Coppa et al., the numerical value found higher than Bao et al..Although from difference research (bag
Include this research) quantitative result show huge difference, but generally had been found that acid sugar in age of sucking in first month
Being decreased obviously of fraction entirety and great majority individually sugar.
6 '-SL and LSTc decline in a similar manner, this following hypothesis of true support: single sialyltransferase,
Being probably ST6Gall, unique 2 type structures accepted participate in the biosynthesis of these carbohydrates.LSTc more significantly under
Fall can be explained with the decline of the precursor core LNnT of LSTc, but the amount of the precursor lactose of 6 '-SL is producing one week after
Rear holding is constant.The 3 '-SL that during research, little degree declines can be synthesized (two kinds of α 2,3-by ST3Gal IV or ST3Gal VI
2 type structures are preferentially worked by sialyltransferase), and it is the most to the inventors discovered that secondary acid sugar LSTa declines,
Can not or can only partly detect behind 2 and 3 months.The present inventor guesses the 2,3-sialic acid preferentially worked 1 type structure
Transferring enzyme ST3Gall III participates in the biosynthesis of LSTa and DSLNT.LSTb is unique increase in first month puerperal
Acid sugar, the result before which demonstrating.So-called ST6GlcNAc can shift sialic acid moities to the GlcNAc of near-end, produces
Raw LSTb and DSLNT (a kind of oligosaccharide showing that α 2,6-connects and α 2,3-connection neuraminic acid).
Embodiment 2 infant formula
The every 100ml of infant formula (dry weight 13.9g) comprises:
1.4g protein (milk surum and casein)
7.3g digestible carbohydrates (includes lactose)
3.6g fat (vegetablefats, fish oil)
1.03g non-digestible property oligosaccharide, wherein has 120mg 6 '-SL, 30mg 3 '-SL, 80mg 2 '-fucosido breast
Sugar, 720mg β-oligomeric galactose and 80mg oligofructose
Farther include: choline, inositol, taurine, mineral, trace element and vitamin known in the art.
Embodiment 3 child's dairy compositions
Child's dairy compositions (for 1-3 year baby's design) every 100ml (67kcal；Dry weight 15.1g) including:
1.5g protein (lactalbumin/casein 1/1w/w)
8.5g digestible carbohydrates (wherein has 6.0g lactose, 1.1g maltodextrin)
3.0g fat (vegetablefats)
1.23g non-digestible property oligosaccharide, wherein has 120mg 6 '-SL, 30mg 3 '-SL, 80mg 2 '-fucosido breast
Sugar, 900mg β-oligomeric galactose and 100mg oligofructose
Mineral, trace element, vitamin known in the art, include choline and taurine.
Claims (12)
1. the compositions comprising 6 '-sialylated lactose (6 '-SL) provides the nutrient combination of nutrition for being prepared as baby
The purposes of thing, described alimentation composition comprises at least 1g/L 6 '-SL, and the ratio of wherein 6 '-SL:3 '-SL is higher than 2.
Purposes the most according to claim 1, the concentration of wherein said 6 '-SL is at least 1.1g/L.
3., according to the purposes of claim 1 or 2, the ratio of wherein said 6 '-SL:3 '-SL is higher than 3.
4., according to the purposes of aforementioned any one of claim, the ratio of wherein said 6 '-SL:3 '-SL is higher than 4.
5. according to the purposes of aforementioned any one of claim, wherein said alimentation composition farther include selected from oligofructose and
The non-digestible property oligosaccharide of oligomeric galactose.
6., according to the purposes of aforementioned any one of claim, wherein said alimentation composition farther includes selected from galacturonic acid
Oligosaccharide and the uronic acid oligosaccharides of pectin degradation product.
7., according to the purposes of aforementioned any one of claim, wherein said compositions includes providing total caloric 35%-50%
Lipid, it is provided that the protein of total caloric 7.5%-12.5%, and digesting of total caloric 40%-55% is provided
Property carbohydrate.
8., according to the purposes of aforementioned any one of claim, wherein said alimentation composition is for providing to the baby of 0-36 month
Nutrition.
9., according to the purposes of aforementioned any one of claim, wherein said alimentation composition is for providing to the baby of 0-6 month
Nutrition.
10. an alimentation composition, including providing total caloric 35%-50% fat, it is provided that total caloric 7.5%-
12.5% protein, and total caloric 40%-55% digestible carbohydrates is provided, and farther include 1-3g/L
6 '-SL, wherein the ratio of 6 '-SL:3 '-SL is between 2.5 to 5.5.
11. alimentation compositions according to claim 10, farther include β-oligomeric galactose, oligofructose and uronic acid oligosaccharide
Sugar.
12. according to the alimentation composition of claim 10 or 11, and it is 1 stage infant formula.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NLPCT/NL2010/050239 | 2010-04-27 | ||
| PCT/NL2010/050239 WO2011136636A1 (en) | 2010-04-27 | 2010-04-27 | Use of 6'-sialyl lactose in infant nutrition |
| EP10162555 | 2010-05-11 | ||
| EP10162555.6 | 2010-05-11 | ||
| CN2011800210644A CN102858191A (en) | 2010-04-27 | 2011-04-27 | Use of 6'-sialyl lactose in infant and toddler nutrition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800210644A Division CN102858191A (en) | 2010-04-27 | 2011-04-27 | Use of 6'-sialyl lactose in infant and toddler nutrition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106072654A true CN106072654A (en) | 2016-11-09 |
Family
ID=44080128
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610421321.8A Pending CN106072654A (en) | 2010-04-27 | 2011-04-27 | 6 ' sialylated lactose purposes in infants and young's nutrient |
| CN2011800210644A Pending CN102858191A (en) | 2010-04-27 | 2011-04-27 | Use of 6'-sialyl lactose in infant and toddler nutrition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800210644A Pending CN102858191A (en) | 2010-04-27 | 2011-04-27 | Use of 6'-sialyl lactose in infant and toddler nutrition |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2563165A1 (en) |
| CN (2) | CN106072654A (en) |
| WO (1) | WO2011136647A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115209745A (en) * | 2019-12-09 | 2022-10-18 | 雀巢产品有限公司 | Composition comprising human milk oligosaccharides for use in supporting language development in an individual |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY166945A (en) | 2010-12-31 | 2018-07-25 | Abbott Lab | Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof |
| MX338174B (en) | 2010-12-31 | 2016-04-06 | Abbott Lab | Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents. |
| NZ612472A (en) | 2010-12-31 | 2015-02-27 | Abbott Lab | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
| CN103391783A (en) | 2010-12-31 | 2013-11-13 | 雅培制药有限公司 | Methods of using human milk oligosaccharides for improving airway respiratory health |
| EP3338784B1 (en) | 2010-12-31 | 2020-07-22 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
| NZ612455A (en) | 2010-12-31 | 2015-02-27 | Abbott Lab | Human milk oligosaccharides to promote growth of beneficial bacteria |
| US9539269B2 (en) | 2010-12-31 | 2017-01-10 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
| WO2012107865A2 (en) * | 2011-02-10 | 2012-08-16 | Wyeth Llc | Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk |
| SG2014013478A (en) | 2011-08-29 | 2014-05-29 | Abbott Lab | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| EP2836218A4 (en) * | 2012-04-13 | 2015-10-21 | Trustees Boston College | Prebiotic compositions and methods of use |
| EP2745705A1 (en) * | 2012-12-18 | 2014-06-25 | Abbott Laboratories | Nutritional use of human milk oligosaccharides |
| ES2725464T3 (en) | 2014-09-25 | 2019-09-24 | Nestle Sa | Infant formula system with adaptive levels of human milk oligosaccharides (OLH) |
| US20180103675A1 (en) * | 2016-10-14 | 2018-04-19 | Mead Johnson Nutrition Company | Personalized pediatric nutrition products comprising human milk oligosaccharides |
| JP2021505171A (en) * | 2017-12-08 | 2021-02-18 | イェンネワイン バイオテクノロジー ゲーエムベーハーＪｅｎｎｅｗｅｉｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅ ＧｍｂＨ | Spray-dried sialyll lactose |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1406111A (en) * | 2000-02-17 | 2003-03-26 | 惠氏公司 | Nutritional formulation containing prebiotic substances |
| CN1863463A (en) * | 2003-06-23 | 2006-11-15 | 雀巢技术公司 | Nutritional formula for optimal gut barrier function |
| WO2010002241A1 (en) * | 2008-06-30 | 2010-01-07 | N.V. Nutricia | Nutritional composition for infants delivered via caesarean section |
| CN102065872A (en) * | 2008-05-27 | 2011-05-18 | 雀巢产品技术援助有限公司 | Probiotics to improve gut microbiota |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL1027262C2 (en) * | 2004-04-08 | 2005-10-13 | Friesland Brands Bv | Composition for reducing intestinal wall permeability, used in e.g. baby food, comprises whey protein, proline and sialic acid |
| EP2060257A1 (en) * | 2007-11-08 | 2009-05-20 | Nestec S.A. | Prevention and treatment of secondary infections following viral infection |
| NL2001377C2 (en) | 2008-03-14 | 2009-09-15 | Friesland Brands Bv | Process for isolating sialic acid-containing oligosaccharides, as well as the compositions containing sialic acid-containing oligosaccharides. |
| EP2143341A1 (en) * | 2008-07-08 | 2010-01-13 | Nestec S.A. | Nutritional Composition Containing Oligosaccharide Mixture |
-
2011
- 2011-04-27 WO PCT/NL2011/050285 patent/WO2011136647A1/en active Application Filing
- 2011-04-27 EP EP11720599A patent/EP2563165A1/en not_active Ceased
- 2011-04-27 CN CN201610421321.8A patent/CN106072654A/en active Pending
- 2011-04-27 CN CN2011800210644A patent/CN102858191A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1406111A (en) * | 2000-02-17 | 2003-03-26 | 惠氏公司 | Nutritional formulation containing prebiotic substances |
| CN1863463A (en) * | 2003-06-23 | 2006-11-15 | 雀巢技术公司 | Nutritional formula for optimal gut barrier function |
| CN102065872A (en) * | 2008-05-27 | 2011-05-18 | 雀巢产品技术援助有限公司 | Probiotics to improve gut microbiota |
| WO2010002241A1 (en) * | 2008-06-30 | 2010-01-07 | N.V. Nutricia | Nutritional composition for infants delivered via caesarean section |
Non-Patent Citations (1)
| Title |
|---|
| YUANWU BAO ET AL.: "Simultaneous quantification of sialyloligosaccharides from human milk by capillary electrophoresis", 《ANALYTICAL BIOCHEMISTRY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115209745A (en) * | 2019-12-09 | 2022-10-18 | 雀巢产品有限公司 | Composition comprising human milk oligosaccharides for use in supporting language development in an individual |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2563165A1 (en) | 2013-03-06 |
| CN102858191A (en) | 2013-01-02 |
| WO2011136647A1 (en) | 2011-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106072654A (en) | 6 ' sialylated lactose purposes in infants and young's nutrient | |
| US11135290B2 (en) | Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit | |
| US11090321B2 (en) | Mixture of non-digestible oligosaccharides for stimulating the immune system | |
| CN101945589A (en) | Use of non-digestible carbohydrates for improving intestinal microbiota | |
| EP2563166B1 (en) | Use of human milk oligosaccharides in infant nutrition | |
| TW201225852A (en) | Oligosaccharide mixture and food product comprising this mixture, especially infant formula | |
| CN101987107A (en) | Immunemodulating oligosaccharides | |
| WO2011136636A1 (en) | Use of 6'-sialyl lactose in infant nutrition | |
| TW201824998A (en) | Personalized pediatric nutrition products comprising human milk oligosaccharides | |
| CN1871015B (en) | Immunemodulating oligosaccharides | |
| WO2011136637A1 (en) | Use of human milk oligosaccharides in infant nutrition | |
| Zhao | Oligosaccharides in Food | |
| CA3198961A1 (en) | Synthetic compositions comprising lnfp iii and lsta | |
| BR122021007429B1 (en) | USE OF 2'-FUCOSYLACTOSIS IN THE MANUFACTURING OF AN ENTERAL COMPOSITION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161109 |